Despite the huge task of implementing new serialisation technologies and processes, many pharmaceutical companies have delayed involving contract partners in their serialisation efforts, adopting a ‘wait and see’ approach.

It is imperitive that pharmaceutical companies choose contract partners that are prepared for serialisation.

However, as the final countdown to legislation begins it is imperative that drug manufacturers select contract partners that are well-prepared and able to comprehensively cater for global regulatory requirements.

Our Director – Corporate Projects and Serialisation Programme Manager, Staffan Widengren, talks to Pharmaceutical Technology about the importance of selecting the right contract partner to ensure complete compliance come the deadlines.

Read the full article here

PharmTech, Feb 01, 2017